Post by
Wino115 on Feb 28, 2023 9:20am
Bit of clarity on oncology thoughts from CMO
Last Q was interesting and sort of backs up some here who thought patient selection should have been better optimized. Christian was pretty clear on some points.
1. The construct of the PDC (target, linker) doesn't appear to be an issue. "Lots of testing".
2. Dosing schedules will be tested (maybe not just one) to increase efficacy.
3. Better patient selection has to be part of protocol.
4. Prior treatment numbers seems to have shown some correlation with effect (probably more a taxol resistance issue?)
5. Tumor types will be narrowed to those where there was "some success".
As Levesque said, what ever can be done to optimize getting efficacy results, then partner. Will be interesting to see what Marsolais thinks is what comes out from all the experts. Still has hurdles, but at least a whole new set of experienced outside eyes will be brought into the discussion.
Comment by
scarlet1967 on Feb 28, 2023 9:30am
He said patient selection will be based on tumors they saw some efficacy well that was the reason why they chose certain cancers for the basket trials already! To me it sounds like they also saw efficacy in the part2 so they will narrow down f the selection of patients/tumors to fewer tumor types.